Compare Angi Inc (ANGI) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Angi Inc vs BridgeBio Pharma Inc — how do they compare? Angi Inc trades at $4.5 (market cap $186.15M), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 89.2× Angi Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.
| ANGI | BBIO | |
|---|---|---|
Market Cap | $186.15M | $16.61B |
Sector | Media | Health |
52-Week High | $18.46 | $90.17 |
52-Week Low | $4.49 | $47.29 |
Enterprise Value | $395.93M | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $4.84, down 2.42% on the day, with a bearish technical signal and mixed earnings history. Revenue has declined from $1.9B in 2022 to $1.03B in 2025, though net income turned positive in 2024-2025 before a projected loss in 2026. The stock trades at low valuation multiples (P/E 14.81, P/S 0.21), but faces challenges with negative ROE and ROA. Recent news highlights Q2 2026 earnings misses and ongoing investigations into the company.
The outlook is cautious due to declining revenue, accelerating pro user churn, and negative cash flow projections. Analyst consensus is a $7.00 price target with a 'Hold' bias, but risks include platform deterioration, legal scrutiny, and lack of clear catalysts. Upside depends on stabilizing the core marketplace and executing a viable AI strategy.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
